Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

Phase 2

Terminated

• Conditions: Nonalcoholic Fatty Liver Disease
• Interventions: Drug: Saroglitazar Magnesium 4 mg; Drug: Placebo

• Registration Number: NCT05211284
• Lead Sponsor: Zydus Therapeutics Inc.

Brief Summary

Saroglitazar Magnesium 4 mg for NASH in People Living with HIV in the US

Detailed Description

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis (NASH) in People Living with Human Immunodeficiency Virus (HIV) in the US

Study Timeline

• Study First Submitted: 2022-01-24
• Study First Submitted QC: 2022-01-24
• Study First Posted: 2022-01-27
• Study Start: 2022-12-08
• Primary Completion: 2023-10-02
• Study Completion: 2023-10-02
• Disposition First Posted: 2024-09-23
• Disposition First Submitted: 2024-10-01
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-29
• Last Update Posted: 2024-12-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

1. Adults (≥18 years of age) with documented HIV.
2. Histologic confirmation of NASH from liver biopsy within 6 months prior to screening or planned clinical biopsy in patients with suspected NASH pending confirmation of liver biopsy criteria including a NAS ≥4 (with at least one-point each for steatosis, lobular inflammation, and ballooning).
3. HIV-1 RNA <50 copies/mL for ≥6 months on ART (must have screening HIV-1 RNA value and one clinical care value within 6 months prior to screening and up to the randomization that meets the criteria).
4. Stable ART regimen for ≥3 months prior to screening and stable up to the randomization and no active plans to change ART while on study.
5. Willingness to participate in the study and undergo an EOT liver biopsy

Exclusion Criteria

1. History of significant alcohol consumption (defined as >2 drinks/day on average for men, >1 drinks/day on average for women) for at least 3 consecutive months (12 consecutive weeks) within 5 year before screening (Note 1: 1 drink =12 ounces of beer, 8-9 ounces of malt liquor, 4 ounces of wine or 1 ounce of spirits/hard liquor. Note 2: Use sex assigned at birth for alcohol consumption limits).

2. History of other acute or chronic liver disease, including, but not limited to autoimmune, primary biliary cholangitis, Wilson's disease, alpha 1 antitrypsin deficiency, hemochromatosis, hepatitis B virus (HBV), and ongoing or recent (within the past 3 years) hepatitis C RNA positivity. (Exceptions: a. Participants with previously treated hepatitis C infection are eligible for consideration if their sustained virologic response was achieved more than 3 years prior to screening. The proportion of such participants in this trial will not exceed 25% of the study cohort. b. Participants with prior acute HBV infection that is resolved but currently do not have hepatitis B surface antigen (HBsAg) or detectable HBV Deoxyribonucleic acid (HBV DNA) are eligible).

3. History of liver transplant.

4. Liver biopsy or radiologic imaging consistent with the clinical presence of cirrhosis or portal hypertension at screening.

5. Participants whose Visit 2 ALT, AST, or alkaline phosphatase (ALP) values exceed their Visit 1 values by more than 50%. Note: These participants will be required to have a third value measured to assess for a trend. If the third value shows a continued increase ≥10% compared to the Visit 2 values, the participant is considered ineligible for randomization.

6. Ongoing use of steatogenic medications or supra-physiologic hormonal therapies (exception: transgender women on stable dose [for ≥3 months] of feminizing hormonal therapy), within 3 months prior to screening or historical liver biopsy until time of randomization or anticipated use of medications that cause significant changes in weight during the study period; (Refer Appendix 7 for 'List of Medications').

7. Uncontrolled type 2 diabetes mellitus, defined as HbA1c >9.5% at screening.

8. Any of the following laboratory values at screening:

   1. ALT or AST >250 U/L.
   2. Total bilirubin >1.5 mg/dL and direct bilirubin > 0.5 mg/dL (unless due to Gilbert's disease or atazanavir use per the opinion of the site investigator).
   3. Platelet count <150,000/mm3.
   4. Estimated glomerular filtration rate (e-GFR) <60 mL/min/1.73m2 using the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation (Refer Appendix 6 for 'CKD-EPI Calculator').
   5. International normalized ratio (INR) >1.3.
   6. Albumin < 3.6 g/dL

9. History of malignancy in the past 5 years and/or active neoplasm with the exception of superficial, non-melanoma, skin cancer.

10. Participants with child-bearing potential (pregnancy or inability or unwilling to practice contraception for the study duration) or breast-feeding.

11. Unstable cardiovascular disease, including:

    1. Unstable angina, (i.e., new or worsening symptoms of coronary heart disease) and/or acute myocardial infarction within the 3 months preceding screening
    2. Acute coronary syndrome or coronary artery intervention, within the 6 months preceding screening
    3. Heart failure of New York Heart Association (NYHA) class (III-IV) or worsening congestive heart failure within the 6 months preceding screening.
    4. History of (within 3 months preceding screening) or current unstable cardiac dysrhythmias.
    5. Uncontrolled hypertension (systolic blood pressure [SBP] >155 mm Hg and/or diastolic blood pressure [DBP] >95 mm Hg) at screening.
    6. Stroke or transient ischemic attack within the 6 months preceding screening.

12. Unstable pulmonary disease (based upon site investigator's evaluation) at screening.

13. Use of drugs that are known CYP2C8 inhibitors/substrates (Refer Appendix 2 for the 'List of Known CYP2C8 inhibitors/substrates') in the last 28 days preceding screening.

14. History of severe illness or any other conditions (such as poorly controlled psychiatric disease, active gastrointestinal conditions that might interfere with drug absorption, etc.) that require systemic treatment/or hospitalization, until participant either completes therapy or is clinically stable on therapy as per the opinion of the site investigator, for at least 7 days prior to screening.

15. Use of other PPAR agonists (fibrates, thiazolidinediones, telmisartan) within 6 months prior to screening or historical liver biopsy until time of randomization.

16. Use of unstable doses of sodium-glucose cotransporter-2 (SGLT2) inhibitors (e.g. canagliflozin, empagliflozin, dapagliflozin, etc.) or glucagon-like peptide (GLP)-1 agonists (e.g. exenatide, liraglutide, lixisenatide, etc.) within 6 months prior to screening or historical liver biopsy until time of randomization.

17. Use of pentoxifylline, ursodeoxycholic acid, antioxidants such as vitamin E (>200 IU/day), glutathione, orlistat, betaine, incretin mimetics or non-prescribed complementary alternative medications within 6 months prior to screening or historical liver biopsy until time of randomization.

18. Known allergy, sensitivity or intolerance to the study medication or formulation ingredients.

19. History of any known bleeding disorder or coagulopathy.

20. Any condition that in the opinion of the site investigator, would compromise the participant's ability to participate in the study.

21. Unstable doses of anti-diabetic agents, including sulfonylureas, biguanides or dipeptidyl peptidase-4 (DPP-4) inhibitors in the last 3 months prior to screening or historical liver biopsy until time of randomization.

22. Unstable doses of lipid-lowering agents such as statins (e.g. simvastatin, pravastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin, etc.) in the last 3 months prior to screening or historical liver biopsy until time of randomization.

23. Participant with weight change >5% within 6 months prior to screening or historical liver biopsy until time of randomization.

24. History of bariatric surgery or currently undergoing evaluation for bariatric surgery.

25. Participation in another interventional clinical study and/or receipt of any other investigational medication within 3 months prior to screening or historical liver biopsy .

26. History of COVID-19 infection in the last 30 days prior to screening.

27. Pregnancy-related exclusions, including:

    1. Pregnant/lactating female (including positive pregnancy test at screening)
    2. Fertile women participants and their male counterparts or vice versa, not using effective contraceptive methods (such as an intra-uterine contraceptive device, other mechanical contraceptive methods like use of condom and diaphragm along with spermicide, or hormonal contraceptives that inhibit ovulation) throughout the study.

(Note: Enrolled females otherwise must be surgically sterilized for at least 24 weeks before screening; postmenopausal, defined as 52 weeks with no menses without an alternative medical cause; or following sexual abstinence).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Saroglitazar Magnesium 4 mg	Saroglitazar Magnesium 4 mg	Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks)
Placebo Arm	Placebo	Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks).

Primary Outcome Measures

Name	Time	Method
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in hepatic fat content measured by MRI Proton Density Fat fraction (MRI PDFF)	Week 24/EOT	Change from baseline in hepatic fat content

Secondary Outcome Measures

Name	Time	Method
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on reduction of hepatic fat content as measured by MRI PDFF.	Week 24/EOT	Proportion of participants with reduction of at least 30% in hepatic fat content from baseline
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in FibroScan®/VCTE .	Week 24/EOT	Change from baseline in Liver Stiffness Measurement
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in FibroScan®/VCTE	Week 24/EOT	Change from baseline in Continuous Controlled Attenuation Parameter
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in FibroScan®/Vibration-controlled transient elastography (VCTE).	Week 24/EOT	Change from baseline in Fibroscan-aspartate aminotransferase (FAST) score
To evaluate the effects of Saroglitazar Magnesium 4 mg compared with Placebo on changes in non-invasive markers of fibrosis and steatosis	Week 24/EOT	Change from baseline in Nonalcoholic fatty liver disease Fibrosis Score (NFS) The NFS is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio.; NFS was calculated using the following formula: NAFLD fibrosis score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl).; A decrease in NFS score represents a positive outcome. An NFS score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis.
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on liver enzyme	Week 24/EOT	Change from baseline in liver enzyme parameters (ALT and AST)
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on lipid profile	Week 24/EOT	Change from baseline in triglyceride \[TG), high-density lipoprotein \[HDL\], low-density lipoprotein \[LDL\], very low-density lipoprotein \[VLDL\], total cholesterol, and non-HDL cholesterol
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on fasting glucose	Week 24/EOT	Change from baseline in fasting plasma glucose (FPG)
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on anthropometric measurements.	Week 24/EOT	Change from baseline in hip circumference and minimum waist circumference
To evaluate the effect of Saroglitazar Magnesium 4 mg compared with Placebo on changes in Health-related quality of life scores measured by Short Form-36 (SF-36) Questionnaire.	Week 24/EOT.	Change from baseline in SF-36 Questionnaire mental (MCS) and physical components scores (PCS). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status.

Trial Locations

Locations (8)

Zydus US002; 🇺🇸 Indianapolis, Indiana, United States

Zydus US004; 🇺🇸 Birmingham, Alabama, United States

Zydus US005; 🇺🇸 La Jolla, California, United States

Zydus US006; 🇺🇸 San Francisco, California, United States

Zydus US003; 🇺🇸 Baltimore, Maryland, United States

Zydus US001; 🇺🇸 Durham, North Carolina, United States

Zydus US007; 🇺🇸 Houston, Texas, United States

Zydus US008; 🇺🇸 Richmond, Virginia, United States